https://doi.org/10.1080/10826084.2024.2340975 |
https://doi.org/10.1186/s42238-024-00234-y |
http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2264-1047 |
Cannabis use in the COVID-19 pandemic: Changes in different populations and implications for policy in Linking Neuroscience and Behavior in COVID-19Created by Adam Zaweel, Isaac Kuk, Soyeon Kim, Bernard Le Foll, Christine Wickens. |
https://www.mdpi.com/2076-3425/14/4/356 |
Participant Fraud in Virtual Qualitative Substance Use Research: Recommendations and Considerations for Detection and Prevention Based on a Case StudyCreated by Madison Wright, Justin Matheson, Tara Marie Watson, Beth Sproule, Bernard Le Foll, Bruna BrandsThe COVID-19 pandemic has accelerated and amplified the use of virtual research methods. While online research has several advantages, it also provides greater opportunity for individuals |
https://www.mdpi.com/2076-3425/14/3/246 |
https://journals.sagepub.com/doi/abs/10.1177/07067437231210796 |
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic TrialCreated by Anees Bahji, Gabriel Bastien, Paxton Bach, JinCheol Choi, Bernard Le Foll, Ron Lim, Didier Jutras-Aswad & M. Eugenia Socias.Prescription-type opioid use disorder (POUD) is often accompanied by comorbid anxiety, yet the impact of anxiety on retention in opioid agonist therapy (OAT) is unclear. Therefore, this study investigated… |
Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/NaloxoneCreated by Intishar Kazi, Meghan Chenoweth, Didier Jutras-Aswad, Keith Ahamad, M. Eugenia Socias, Bernard Le Foll, Rachel TyndaleMethadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response… |
https://doi.org/10.1186/s12906-023-04312-1 |
https://doi.org/10.1001/jamanetworkopen.2023.52233 |
https://doi.org/10.1016/j.brs.2024.01.008 |
Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trialsCreated by Heidar Sharafi, Hamzah Bakouni, Christina McAnulty, Sarah Drouin, Stephanie Coronado-Montoya, Arash Bahremand, Paxton Bach, Nadine Ezard, Bernard Le Foll…There is currently no standard of care for pharmacological treatment of amphetamine-type stimulant (ATS) use disorder (ATSUD). This systematic review with meta-analysis (PROSPERO CRD42022354492) aimed to pool results from randomized placebo-controlled trials (RCTs) to evaluate efficacy and safety of prescription psychostimulants (PPs) for ATSUD… |
https://www.cmaj.ca/content/196/6/E187 |
...